Minimal phenotype panels - A method for achieving maximum population coverage with a minimum of HLA antigens

被引:25
作者
Schipper, RF
vanEls, CACM
DAmaro, J
Oudshoorn, M
机构
[1] LEIDEN UNIV HOSP,BLOOD BANK,NL-2300 RC LEIDEN,NETHERLANDS
[2] NATL INST PUBL HLTH & ENVIRONM HYG,LAB VACCINE DEV & IMMUNE MECH,BILTHOVEN,NETHERLANDS
关键词
D O I
10.1016/S0198-8859(96)00138-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination with peptides that induce a specific immune response is a potential prophylactic or therapeutic strategy against viral infections and tumors. Because of the extensive polymorphism of the HLA loci, synthetic peptide vaccines muse consist of a cocktail of peptides that bind specifically to different HLA molecules. Such cocktails should be optimized for the target population as each population has its specific KLA gene frequencies. To achieve maximum population coverage with a minimum number of peptides, information is needed on the ranking of the most frequent HLA phenotypes. We introduce the minimal phenotype panel, which is the smallest combination of HLA antigens selected so that the proportion of individuals in a population that express at least one of the antigens in the panel exceeds a desired minimum value. We developed a method for assembling minimal phenotype panels based on known HLA class I gene frequencies. We give an example based on a set of 2446 well-defined HLA-typed, random, healthy, unrelated, Dutch Caucasoid individuals. In addition, we discuss the possibility of assembling minimal phenotype panels based on two-locus haplotypes, which enables the assembly of phenotype panels from the antigens of both loci. (C) American Society for Histocompatibility and Immunogenetics, 1996.
引用
收藏
页码:95 / 98
页数:4
相关论文
共 12 条
  • [1] BLEEK GM, 1993, CHEM IMMUNOL, V57, P1
  • [2] HUMAN TRIALS OF EXPERIMENTAL AIDS VACCINES
    FAST, PE
    WALKER, MC
    [J]. AIDS, 1993, 7 : S147 - S159
  • [3] VACCINATION WITH CYTOTOXIC T-LYMPHOCYTE EPITOPE-CONTAINING PEPTIDE PROTECTS AGAINST A TUMOR-INDUCED BY HUMAN PAPILLOMAVIRUS TYPE-16-TRANSFORMED CELLS
    FELTKAMP, MCW
    SMITS, HL
    VIERBOOM, MPM
    MINNAAR, RP
    DEJONGH, BM
    DRIJFHOUT, JW
    TERSCHEGGET, J
    MELIEF, CJM
    KAST, WM
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (09) : 2242 - 2249
  • [4] Kast W M, 1991, Int J Cancer Suppl, V6, P90
  • [5] LAGAAY AM, 1991, PHYSL SENESCENCE ITS
  • [6] IMMUNIZATION AGAINST POLYOMA TUMORS WITH SYNTHETIC PEPTIDES DERIVED FROM THE SEQUENCES OF MIDDLE-T AND LARGE-T ANTIGENS
    REINHOLDSSONLJUNGGREN, G
    RAMQVIST, T
    AHRLUND-RICHTER, L
    DALIANIS, T
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (01) : 142 - 146
  • [7] PEPTIDE-INDUCED ANTIVIRAL PROTECTION BY CYTOTOXIC T-CELLS
    SCHULZ, M
    ZINKERNAGEL, RM
    HENGARTNER, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (03) : 991 - 993
  • [8] SYNTHETIC PEPTIDE LIBRARIES IN THE DETERMINATION OF T-CELL EPITOPES AND PEPTIDE BINDING-SPECIFICITY OF CLASS-I MOLECULES
    SCHUMACHER, TNM
    VANBLEEK, GM
    HEEMELS, MT
    DERES, K
    LI, KW
    IMARAI, M
    VERNIE, LN
    NATHENSON, SG
    PLOEGH, HL
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (06) : 1405 - 1412
  • [9] HLA-A2-BINDING PEPTIDES CROSS-REACT NOT ONLY WITHIN THE A2 SUBGROUP BUT ALSO WITH OTHER HLA-A-LOCUS ALLELIC PRODUCTS
    TANIGAKI, N
    FRUCI, D
    CHERSI, A
    FALASCA, G
    TOSI, R
    BUTLER, RH
    [J]. HUMAN IMMUNOLOGY, 1994, 39 (03) : 155 - 162
  • [10] VANDERBURG SH, 1995, AIDS, V9, P121, DOI 10.1097/00002030-199509020-00002